- Home
- IRIX vs RNXT Comparison
IRIX vs RNXT Comparison
Compare IRIX & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRIX
- RNXT
- Stock Information
- Founded
- IRIX 1989
- RNXT 2012
- Country
- IRIX United States
- RNXT United States
- Employees
- IRIX N/A
- RNXT N/A
- Industry
- IRIX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- IRIX Health Care
- RNXT Health Care
- Exchange
- IRIX Nasdaq
- RNXT Nasdaq
- Market Cap
- IRIX 23.8M
- RNXT 21.6M
- IPO Year
- IRIX 1996
- RNXT 2021
- Fundamental
- Price
- IRIX $1.72
- RNXT $1.21
- Analyst Decision
- IRIX Hold
- RNXT Strong Buy
- Analyst Count
- IRIX 1
- RNXT 2
- Target Price
- IRIX $2.00
- RNXT $6.13
- AVG Volume (30 Days)
- IRIX 44.0K
- RNXT 42.6K
- Earning Date
- IRIX 11-12-2024
- RNXT 11-13-2024
- Dividend Yield
- IRIX N/A
- RNXT N/A
- EPS Growth
- IRIX N/A
- RNXT N/A
- EPS
- IRIX N/A
- RNXT N/A
- Revenue
- IRIX $48,431,000.00
- RNXT N/A
- Revenue This Year
- IRIX N/A
- RNXT N/A
- Revenue Next Year
- IRIX $5.44
- RNXT N/A
- P/E Ratio
- IRIX N/A
- RNXT N/A
- Revenue Growth
- IRIX N/A
- RNXT N/A
- 52 Week Low
- IRIX $1.27
- RNXT $0.53
- 52 Week High
- IRIX $3.65
- RNXT $2.35
- Technical
- Relative Strength Index (RSI)
- IRIX 55.76
- RNXT 68.06
- Support Level
- IRIX $1.65
- RNXT $1.04
- Resistance Level
- IRIX $1.85
- RNXT $1.18
- Average True Range (ATR)
- IRIX 0.13
- RNXT 0.10
- MACD
- IRIX 0.04
- RNXT 0.01
- Stochastic Oscillator
- IRIX 67.16
- RNXT 78.61
About IRIX IRIDEX Corporation
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.